CABA insider buying and SEC filings, explained
Cabaletta Bio, Inc. · CIK 1759138
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$286K
Insiders who bought
7
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jan 21, 2026 | Purchase (code P) | David J. Chang (Chief Medical Officer) bought 8,800 shares at $2.26 ($20K), reported as a purchase (code P). New position of 8,800 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 21, 2026 | Purchase (code P) | Gwendolyn Binder (President / COO) bought 11,312 shares at $2.19 ($25K), reported as a purchase (code P). Holdings up 57% to 31,312 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 21, 2026 | Purchase (code P) | Shawn Tomasello (Director) bought 22,725 shares indirectly (by entity) at $2.21 ($50K), reported as a purchase (code P). New position of 22,725 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 21, 2026 | Purchase (code P) | Steve Gavel (Chief Commercial Officer) bought 22,170 shares at about $2.27 ($50K), reported as a purchase (code P). New position of 22,170 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 21, 2026 | Purchase (code P) | Catherine Bollard (Director) bought 4,405 shares at $2.27 ($10K), reported as a purchase (code P). Holdings up 441% to 5,405 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 21, 2026 | Purchase (code P) | Steven Nichtberger (CEO and Director) bought 45,000 shares at about $2.24 ($101K), reported as a purchase (code P). Holdings up 5% to 1,031,483 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 21, 2026 | Purchase (code P) | Mark Simon (Director) bought 11,061 shares at about $2.28 ($25K), reported as a purchase (code P). Holdings up 8% to 147,205 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 21, 2026 | Purchase (code P) | Michael Gerard (General Counsel) bought 6,600 shares at about $2.27 ($15K), reported as a purchase (code P). New position of 6,600 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
11 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
7 insiders bought in 30 days
$286K in purchases since Jan 21, 2026 · Purchases traded Jan 21, 2026 to Jan 21, 2026 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Michael Gerard (General Counsel) | $15K | Jan 21, 2026 | SEC filing |
| Mark Simon (Director) | $25K | Jan 21, 2026 | SEC filing |
| Steven Nichtberger (CEO) | $101K | Jan 21, 2026 | SEC filing |
| Steve Gavel (Chief Commercial Officer) | $50K | Jan 21, 2026 | SEC filing |
| Shawn Tomasello (Director) | $50K | Jan 21, 2026 | SEC filing |
| Gwendolyn Binder (President / COO) | $25K | Jan 21, 2026 | SEC filing |
| David J. Chang (Chief Medical Officer) | $20K | Jan 21, 2026 | SEC filing |
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow CABA in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.